Physician profile
Azeem Elahi
NPI 1780811091
$16,808.21
in general payments reported to CMS, 2019-2025
27 companies · $7,635 in 2025
The $7,635 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $105 · 2021: $15.93 · 2022: $277 · 2023: $7,486 · 2024: $1,290 · 2025: $7,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,966 · Education: $5,598 · Food and Beverage: $2,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,966.39 |
| Education | $5,597.99 |
| Food and Beverage | $2,846.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,456.49 | 2023-2025 | Ion, Da Vinci Surgical System |
| Olympus Corporation of The Americas | $1,921.48 | 2023-2025 | Single Use Suction Valve (Sterile), Spiration Valve System |
| Pulmonx Corporation | $1,420.70 | 2020-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Noah Medical Corporation | $896.30 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $298.94 | 2024 | Breztri, Airsupra, Fasenra |
| Olympus America INC. | $250.84 | 2025 | Spiration Valve System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.21 | 2023-2025 | Ofev, Jascayd |
| Inari Medical, INC. | $151.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2022 | |
| Stryker Corporation | $117.59 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $116.00 | 2023-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Galvanize Therapeutics, INC | $109.09 | 2023 | Aliya System |
| Verona Pharma, INC. | $107.68 | 2025 | Ohtuvayre |
| Insmed, INC. | $103.93 | 2023-2025 | Arikayce |
| Genzyme Corporation | $68.64 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $64.42 | 2023-2024 | Tyvaso |
| Pinnacle Biologics, INC | $61.41 | 2025 | Photofrin |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Inspire Medical Systems, INC. | $58.92 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $54.59 | 2023-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $38.18 | 2021-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $31.47 | 2024 | Dupixent |
| Mylan Specialty L.P. | $21.20 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $17.47 | 2024 | Zerbaxa |
| Novartis Pharmaceuticals Corporation | $17.23 | 2025 | |
| Ani Pharmaceuticals, INC. | $15.85 | 2024 | Purified Cortrophin Gel |
| Electromed, INC. | $15.24 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeem Elahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.